Dr. Jeffrey M. Peppercorn, MD

Dr. Peppercorn practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Peppercorn's NPI, 1053471599, was assigned on December 12, 2006. Dr. Peppercorn graduated from Harvard Medical School in 1998. Dr. Peppercorn holds Massachusetts license 205640.

Dr. Peppercorn's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Peppercorn's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Peppercorn is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Peppercorn to 1 more hospital, 2 medical groups and 1 community health center, each named with a free account. Dr. Peppercorn's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Peppercorn practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Peppercorn's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Peppercorn is board certified in medical oncology by the American Board of Internal Medicine. Dr. Peppercorn is licensed in Massachusetts.

CMS data shows 539 Medicare services from Dr. Peppercorn across 4 procedure codes in 2024, for 167 Medicare patients. Medicare paid $36,963 for them.

CMS counts 167 Medicare patients who saw Dr. Peppercorn in 2024. The largest group is 65 to 74, with 77 patients. 75% of them have cancer, and 70% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.49, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Peppercorn's median patient age at 72, with 96% women.

In 2024, Dr. Peppercorn wrote 112 Medicare Part D claims for 34 patients. 72% of them were for generic drugs. CMS names the drug for 61 of them, across 3 drugs with 11 or more claims each, at $189,053 in total drug cost. In 2023, CMS named 38 claims across 2 drugs.

Dr. Peppercorn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Peppercorn as offering telehealth.

Dmand AI links 175 papers to Dr. Peppercorn, published from 2008 to 2025. 2022 was the busiest year, with 19. The most frequent topics are Breast Neoplasms, Medical Oncology and Cancer Survivors. Dr. Peppercorn has published most often in Cancer. Dr. Peppercorn's most frequent co-authors are Ann H. Partridge, MD, MPH, Virginia F. Borges, MD and Kathryn Jean Ruddy, MD, MPH.

Dmand AI links Dr. Peppercorn to 2 clinical trials. Conditions studied include Breast Neoplasms, Fasting and Breast Diseases. Massachusetts General Hospital sponsors the most, 2.

CMS Open Payments shows 11 general payments to Dr. Peppercorn from 5 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 94% of the total. Pfizer Inc. paid the most, $45,963.

Dr. Peppercorn graduated from Harvard Medical School in 1998.